Listed companies producing blood purification equipment mainly include Jianfan Bio (300529), Baolite (300246), Hejia Medical (300273) and Huaren Pharmaceutical (300110). Northeast Securities recently released a research report that the blood purification industry market space is huge, whether it is equipment, supplies, drugs or hemodialysis services have greater opportunities.
Jianfan Bio (300529): March 5 after-hours, Jianfan Bio announced that it plans to invest 1.5 billion yuan in Zhuhai to build the medical device industry (blood purification) project, to expand production and enrich the product line. Dare to greatly expand production because of Jianfan biology on its product market prospect is optimistic. According to the company's disclosure, its products blood perfusion device is commonly used in difficult and critical illnesses, in the industry's leading position. At present, the blood perfusion device has covered more than 4000 secondary hospitals and hemodialysis centers.
Baolite (300246): Guangdong Baolite Medical Technology Co., Ltd. was founded in 1993, Baolite company is a collection of research and development, production and sales of medical equipment as one of the modern high-tech enterprises. In terms of blood purification, the company has completed the layout of the whole field of blood purification equipment and consumables through the combination of endogenous development and epitaxial mergers and acquisitions, and owns hemodialysis equipment (machine), hemodialyzer, hemodialysis powder/dialysis solution, perfusion machine, hemodialysis tubing, puncture needles, disinfectant solution, dialysis water equipment, disinfectant system, and concentrate centralized dispensing and supplying system, and other products.
Hejia medical (300273): the company invested 22 million yuan investment Zhuhai Hongsheng (78.75%), Zhuhai Hongsheng core product multi-functional blood purification therapy device (HF400) is currently the most complete domestic and foreign functions, the best treatment mode of one of the blood purification device, the domestic similar products have the highest share of the domestic market (accounting for about 8% of the domestic more than 90% of the imported equipment). More than 90% are imported equipment).
Huaren Pharmaceuticals (300110): In June 2011, the company signed a cooperation agreement with the Institute of Hospital Management of the Ministry of Health, *** with the promotion of Huaren peritoneal dialysis fluid. At the same time, the company's peritoneal dialysis fluid multi-center clinical research project will also be officially launched. After the product is listed on the market, the company will become the only enterprise in China that can produce non-PVC soft-packed peritoneal dialysis solution. The company's peritoneal dialysis fluid business is expected to achieve break-even in 2013, and is expected to grow in volume in 2014-2015.